Belvedere Trading
ABOS icon

Belvedere Trading’s Acumen Pharmaceuticals ABOS Stock Holding History

Belvedere Trading’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,200
Closed -$5.77K – 621
2023
Q2 		$5.77K Buy
+1,200
New +$5.75K ﹤0.01% 747

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return

Belvedere Trading's ABOS Position: Q3 2023 in Review

Belvedere Trading sold out of Acumen Pharmaceuticals (ABOS) in Q3 2023, closing a stake of 12,931 shares — an estimated $62.2K sold.

Belvedere Trading first reported a position in ABOS in Q2 2023 and held it in 1 quarter. The position peaked at $62.2K in Q2 2023. 66 funds tracked by Wall St. Rank hold ABOS as of Q3 2023.

  • Belvedere Trading reported no remaining Acumen Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Belvedere Trading sold 12,931 Acumen Pharmaceuticals shares in Q3 2023, an estimated $62.2K.
  • Belvedere Trading first reported a position in Acumen Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Belvedere Trading's Acumen Pharmaceuticals position peaked at $62.2K in Q2 2023.
  • 66 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q3 2023.

Based on Belvedere Trading's 13F filing for Q3 2023, filed 27 Oct 2023.